Macrolides and ketolides;Macrólidos y cetólidos

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 27, Issue 7, 2009, Pages 412-418

  Cobos Trigueros, Nazaret ^a   Ateka, Oier ^a   Pitart, Cristina ^a   Vila, Jordi ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Macrolides Ketolides Erythromycin

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CYTOCHROME P450 3A4; ERYTHROMYCIN; JOSAMYCIN; KETOLIDE; MACROLIDE; MIOKAMYCIN; PEPTIDYLTRANSFERASE; ROXITHROMYCIN; SPIRAMYCIN; TELITHROMYCIN; TRANSFER RNA;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; BACTERIAL STRAIN; BINDING SITE; CEREBROSPINAL FLUID; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CYTOPLASM; DIARRHEA; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERANCE; HEART VENTRICLE TACHYCARDIA; HEPATITIS; HUMAN; LIVER; LOWER RESPIRATORY TRACT INFECTION; METABOLISM; MICROORGANISM; NAUSEA; NONHUMAN; PREGNANCY; QT PROLONGATION; RESPIRATORY TRACT INFECTION; REVIEW; SPAIN; STREPTOCOCCUS PYOGENES; UPPER RESPIRATORY TRACT INFECTION; URINE; VOMITING;

EID: 68649112782     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2009.06.002     Document Type: Article

References (60)

1. a ed 2002 Academic Press Amsterdam 1 56
2. a ed. Oxford: Butterworth Heinemann; 1997.
3. G. Zhanel, M. Dueck, D.J. Hoban, L.V. Vercaigne, J.M. Embil, and A.S. Gin Review of macrolides and ketolides Drugs 61 2001 443 498
4. J.A. Balfour, and D. Figgitt Telithromycin Drugs 61 2001 815 829
5. F. Namour, D. Wessels, P. Reynolds, E. Sultan, and B. Lenfant Pharmacokinetics of the new ketolide telithomycin (HMR 3647) administered in ascending single and multiples doses Antimicrob Agents Chemother 45 2001 170 175
6. C. Carbon Pharmacodynamics of macrolides, azalides and streptogramins: effect on extracellular pathogens Clin Infect Dis 27 1998 28 32
7. C. Carbon Clinical relevance on intracellular and extracellular concentrations of macrolides Infection 23 Suppl 1 1995 10 14
8. D. Morris, A. De Souza, A. Jones, and W. Morgan High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose Eur J Clin Microbiol Infect Dis 10 1996 859 861
9. a ed 2009 Antares Barcelona
10. D.R. Guay, L.E. Gustavson, K.J. Devcich, J. Zhang, G. Cao, and C.A. Olson Pharmacokinetics and tolerability of extended-release clarithromycin Clin Ther 23 2001 566 577
11. D. Girard, S.M. Finegan, and M.W. Dunne Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models J Antimicrob Chemother 56 2005 365 371
12. J. Williams, and A. Sefton Comparison of macrolides antibiotics J Antimicrob Chemother 31 Suppl C 1993 11 26
13. E. Eisenberg, and M. Barza Azithromycin and clarithromycin J. Remington M. Swartz Current clinical topics in infectious diseases 1994 Blackwell Boston 52 79
14. D. Schlossberg Azithromycin and clarithromycin Med Clin North Am 79 1995 803 815
15. L. Dever, J. Jorgensen, and A. Barbour Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi Antimicrob Agents Chemother 37 1993 1704 1706
16. J. Hamilton-Miller In vitro activities of 14, 15 and 16 membered macrolides against gram-positive cocci J Antimicrob Chemother 29 1992 141 144
17. R. Landinez, J. Liñares, E. Loza, J. Martinez-Beltran, R. Martin, and F. Baquero In vitro activity of azitromycin and tetracycline against 358 clinical isolates of Brucella mellitensis Eur J Clin Microbiol Infect Dis 11 1992 265 267
18. G.W. Amsden Pneumoncoccal macrolide resistance-myth or reality? J Antimicrob Chemother 44 1999 1 6
19. D. Felmingham, G. Zhanel, and D. Hoban Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens J Antimicrob Chemother 48 2001 33 42
20. S. Douthwaite, and W. Champney Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site J Antimicrob Chemother 48 2001 1 8
21. S. Douthwaite Structure-activity relationships of ketolides vs. macrolides Clin Microbiol Infect 7 Suppl 3 2001 11
22. R. Goldman, S. Fesik, and C. Doran Role of protonated and neutral forms of macrolides in binding to ribosomes from gram-positive and gram-negative bacteria Antimicrob Agents Chemother 34 1990 426 431
23. I. Odenholt, E. Lowdin, and O. Cars Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens Antimicrob Agents Chemother 45 2001 23 29
24. M. Labro, J. Benna, and H. Abdelghaffar Modulation of human polymorphonuclear neutrophil function by macrolides: preliminary data concerning dirithromycin J Antimicrob Chemother 31 Suppl C 1993 51 64
25. R. Mizukane, Y. Hirakata, M. Kaku, Y. Ishii, N. Furuya, and K. Ishida Comparative in vitro exoenzyme-suppresing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa Antimicrob Agents Chemother 38 1994 528 533
26. R. Howe, and R. Spencer Macrolides for the treatment of Pseudomonas aeruginosa infections? J Antimicrob Chemother 40 1997 153 155
27. R. Leclercq Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin J Antimicrob Chemother 48 2001 9 23
28. R. Leclercq, and P. Courvalin Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification Antimicrob Agents Chemother 35 1991 1267 1272
29. M. Liu, and S. Douthwaite Activity of the ketolide telithromycin is refractory to erm monomethylation of bacterial rRNA Antimicrob Agents Chemother 46 2002 1629 1633
30. K. Gay, W. Baughman, Y. Miller, D. Jackson, C. Whitney, and A. Schuchat The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: A 6-year population-based assesment J Infect Dis 182 2000 1417 1424
31. A. Díaz, C. Ochoa, M.F. Brezmes, and L. López-Urrutia Correlación entre la prescripción de antibióticos y el descenso de las resistencias a antimicrobianos en el área de salud de Zamora Enferm Infecc Microbiol Clin 27 2009 153 159
32. C. Betriu, E. Culebras, M. Redondo, I. Rodriguez-Avial, M. Gomez, and A. Boloix Prevalence of macrolide and tetracycline resistance mechanims in Streptococcus pyogenes isolates and in vitro susceptibility to telithromycin J Antimicrob Chemother 50 2002 436
33. H. Neu L. Young S. Zinner J. Acar New macrolides, azalides, and streptogramins in clinical practice 1995 Marcel Dekker New York
34. S. Zinner L. Young J. Acar H. Neu Expanding indications for the new macrolides, azalides, and streptogramins 1997 Marcel Dekker New York
35. S. Schonwald, V. Skerk, I. Petricevic, V. Car, M. Misic, and M. Gunjaka Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia Eur J Clin Microbiol Infect Dis 10 1991 877 880
36. P. Gleason, T. Meehan, J. Fine, D. Galusha, and M. Fine Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia Arch Intern Med 159 1999 2562 2572
37. J. Stahl, M. Barza, J. Desjardin, R. Martin, and M. Eckman Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia Arch Intern Med 159 1999 2576 2580
38. J.A. Martínez, J.P. Horcajada, M. Almela, F. Marco, A. Soriano, and E. García Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia Clin Infect Dis 36 2003 389 395
39. E. Garcia, J. Mensa, J.A. Martínez, M.A. Marcos, J. Puig, and M. Ortega Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a β-lactam agent versus a β-lactam agent alone Eur J Clin Microbiol Infect Dis 24 2005 190 195
40. L.M. Baddour, V.L. Yu, K.P. Klugman, C. Feldman, A. Ortqvist, and J. Rello Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia Am J Respir Crit Care Med 170 2004 440 444
41. G.W. Waterer Monotherapy versus combination antimicrobial therapy for pneumococcal pneumonia Curr Opin Infect Dis 18 2005 157 163
42. A. Rodriguez, A. Mendia, J.M. Sirvent, F. Barcenilla, M.V. De la Torre-Prados, and J. Solé-Violán Combination antibiotic therapy improves survival in patients with community -acquired pneumonia and shock Crit Care Med 35 2007 1493 1498
43. V. Dudas, A. Hopefl, R. Jacobs, and B.J. Guglielmo Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals Ann Pharmacother 34 2000 446 452
44. M.L. Metersky, A. Ma, P.M. Houck, and D.W. Bratzler Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones Chest 131 2007 466 473
45. P.M. Houck, Rf. MacLehose, M.S. Niederman, and J.K. Lowery Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states:1993, 1995 and 1997 Chest 119 2001 1420 1426
46. R.B. Brown, P. Iannini, P. Gross, and M. Kunkel Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database Chest 123 2003 1503 1511
47. T.P. Lodise, A. Kwa, L. Cosler, R. Gupta, and R.P. Smith Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia Antimicrob Agents Chemother 51 2007 3977 3982
48. S. Reyes Calzada, R. Martínez Tomas, M.J. Cremades Romero, E. Martínez Moragón, J.J. Soler Cataluña, and R. Menéndez Villanueva Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and readmission Repir Med 101 2007 1909 1915
49. P.G. Charles, M. Whitby, A.J. Fuller, R. Stirling, A.A. Wright, and T.M. Korman The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy Clin Infect Dis 46 2008 1513 1521
50. M.I. Restrepo, E.M. Mortensen, G.W. Waterer, R.G. Wunderink, J.J. Coalson, and A. Anzueto Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Eur Respir J 33 2009 153 159
51. A. Tessmer, T. Welte, P. Martus, M. Schnoor, R. Marre, and N. Suttorp Impact of intravenous β-lactam/macrolide versus β-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia J Antimicrob Chemother 63 2009 1025 1033
52. H. Handsfield, Z. Dalu, D. Martin, J. Douglas, J. McCarty, and D. Schlossberg Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea Sexually Transmitted Dis 21 1994 107 111
53. N. Girgis, T. Butler, R. Frenck, Y. Sultan, F. Brown, and D. Tribble Azitromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance Antimicrob Agents Chemother 43 1999 1441 1444
54. L. Jackson, D. Stewart, S. Wang, D. Cooke, T. Cantrell, and T. Grayston Safety effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease J Antimicrob Chemother 44 1999 411 414
55. A. Stone, M. Mendall, J.C. Kaski, T. Edger, P. Risley, and J. Poloniecki Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflamation and cardiac events in patients with acute coronary syndromes: South thames trial of antibiotics in myocardial infarction and unstable angina (STAMINA) Circulation 106 2002 1219 1223
56. H. Yassim, and L. Dever Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections Exp Opin Invest Drugs 10 2001 353 367
57. S. Catnach, and P. Fairclough Erythromycin and the gut Gut 33 1992 397 401
58. W.A. Ray, K.T. Murray, S. Meredith, S.S. Narasimhulu, K. Hall, and C.M. Stein Oral erythromycin and the risk of sudden death from cardiac causes NEJM 351 2004 1089 1096
59. D.B. Ross The FDA and the case of Ketek. 1 N Engl J Med 356 2007 1601 1604
60. K.D. Clay, J.S. Hanson, S.D. Pope, R.W. Rissmiller, P.P. Purdum 3rd, and P.M. Banks Brief communication: Severe hepatotoxicity of telithromycin: Three case reports and literature review Ann Intern Med 144 2006 415 420